KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Raw Materials: 2017-2021

Historic Raw Materials for Aquestive Therapeutics (AQST) over the last 3 years, with Mar 2021 value amounting to $833,000.

  • Aquestive Therapeutics' Raw Materials fell 35.18% to $833,000 in Q1 2021 from the same period last year, while for Mar 2021 it was $833,000, marking a year-over-year decrease of 35.18%. This contributed to the annual value of $789,000 for FY2020, which is 36.58% down from last year.
  • Per Aquestive Therapeutics' latest filing, its Raw Materials stood at $833,000 for Q1 2021, which was up 5.58% from $789,000 recorded in Q4 2020.
  • In the past 5 years, Aquestive Therapeutics' Raw Materials ranged from a high of $1.4 million in Q1 2019 and a low of $725,000 during Q4 2017.
  • Its 3-year average for Raw Materials is $1.1 million, with a median of $1.2 million in 2020.
  • Per our database at Business Quant, Aquestive Therapeutics' Raw Materials skyrocketed by 76.97% in 2018 and then tumbled by 36.58% in 2020.
  • Over the past 5 years, Aquestive Therapeutics' Raw Materials (Quarterly) stood at $725,000 in 2017, then soared by 76.97% to $1.3 million in 2018, then fell by 3.04% to $1.2 million in 2019, then tumbled by 36.58% to $789,000 in 2020, then slumped by 35.18% to $833,000 in 2021.
  • Its last three reported values are $833,000 in Q1 2021, $789,000 for Q4 2020, and $1.2 million during Q3 2020.